Europe Digital Therapeutics (DTx) Market, By Product (Solutions/Software, Hardware Products, and Services), Application (Treatment, Preventive, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Europe Digital Therapeutics (DTx) Market Analysis and Insights
DTx delivers evidence-based therapeutics to patients that are operated by high-quality software programs to forbid, cope with, or nurse a medical disorder or disease. They are utilized individually or in recital with medicaments, devices, or other remedies to revamp patient care and health upshot. DTx products subsume advanced technology best applications relating to design, clinical affirmations, usability, and data safety. They are corroborated by legislative bodies as required to hold up product asserts regarding peril, potency, and deliberated ply. DTx licenses patients, healthcare providers, and payers with attainable tools for inscribing various conditions through high-standard, sheltered, and virtually data-driven medications.
Data Bridge Market Research analyzes that the Europe Digital Therapeutics (DTx) market is expected to reach USD 3,488.44 million by 2031 from USD 699.24 million in 2023, growing with a CAGR of 23.4% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016-2021) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Product (Hardware Products, Solutions/Software, and Services), Application (Treatment, Preventive, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Denmark, Poland, Sweden, Finland, Norway, and Rest of Europe |
|
Market Players Covered |
Kaia Health, HealthHero, Mindable Health GmbH, GAIA AG, ResMed, and Sidekick Health among others |
Market Definition
Digital Therapeutics (DTx) deliver therapeutic interventions directly to patients using employing evidence-based, remote-assessed software to serve, manage, and avert a broad spectrum of behavioral, mental, and physical disorders. They are utilized alone or mixed with medications, devices, or other therapies to optimize patient care and health outcomes. Rising remote access to therapies that are clinically tested as safe and effective is one of the properties of DTx during the treatment. It provides easy treatment as per the patient’s schedule and in the privacy and safety of their home environment. They are easily available and often accessible through patient-owned devices (smartphones, tablets).
Europe Digital Therapeutics (DTx) Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Technological Advancements in Digital Healthcare Devices
The rapid evolution of technology, encompassing wearable devices, mobile applications, and telehealth platforms, has significantly propelled the market growth. These technological strides enable seamless real-time data collection, transmission, and analysis, empowering healthcare providers with the ability to remotely oversee patients' vital signs, medication adherence, and overall health status. Within the DTx landscape, these advancements have led to the creation of wearable devices and sensors specifically designed for health parameters. These parameters include movement, posture, range of motion, muscle activity, and joint pressure.
These sophisticated wearable devices excel in capturing real-time data, offering objective measurements that empower healthcare providers to remotely monitor patients' MSK conditions and diligently track their progress. The availability of such accurate and reliable wearable devices enhances the efficacy of DTx devices within its broader scope. This integration of cutting-edge technology not only ensures precise data collection but also augments the overall effectiveness of digital therapeutic interventions in managing and improving musculoskeletal health.
- Integration of Artificial Intelligence (AI) and Machine Learning (ML)
AI and ML technologies are being integrated into DTx device systems for MSK conditions. These technologies can analyze large datasets, identify trends, and provide predictive analytics. AI-powered algorithms can assist in identifying potential exacerbations, predicting flare-ups, and personalizing treatment plans based on individual patient data. The integration of AI and ML enhances the accuracy and efficiency of DTx devices.
AI and ML algorithms can process large amounts of data collected from remote monitoring devices, wearables, and other sources. These algorithms can analyze patterns, trends, and correlations in the data to identify potential indicators of MSK conditions, disease progression, and treatment response. AI and ML enable more accurate and timely decision-making for healthcare providers by extracting valuable insights from the data, leading to improved patient care and outcomes.
Opportunity
- Growing Expansion of Telehealth Applications in Europe
Telehealth platforms allow healthcare providers to remotely assess patients, provide guidance, and monitor treatment progress, improving accessibility and convenience for patients with MSK conditions. It allows patients to access healthcare services remotely, eliminating barriers such as geographical distance and limited healthcare infrastructure. More patients can benefit from DTx devices as telehealth continues to expand, regardless of their location. This increased access opens up opportunities for remote monitoring companies to reach a wider patient population and expand their services. Telehealth platforms provide a means for healthcare providers to remotely monitor patients in real time. Through video consultations, secure messaging, and remote monitoring devices, healthcare professionals can monitor vital signs, track progress, and assess patient conditions without the need for in-person visits. DTx devices can be seamlessly integrated into telehealth platforms, allowing for continuous monitoring and personalized care management.
Restraints/ Challenges
- Data Security and Privacy Concerns Related to Data
The transmission and storage of patient health data in remote monitoring systems raise concerns about data security and privacy. Ensuring the protection of patient information and compliance with regulations, such as HIPAA, is crucial to building trust and encouraging the adoption of remote monitoring technologies.
Data security and privacy concerns can lead to patient reluctance to adopt DTx device solutions. Patients may hesitate to share sensitive health information and biometric data if they are unsure about how their data will be protected and who will have access to it. Lack of trust in the security measures implemented by remote monitoring platforms and healthcare providers can hinder patient engagement and limit market growth.
- Software Incompatibility Issues due to Varying Data Standards
In the evolving landscape of the DTx market, the integration and exchange of data among diverse software systems, including Electronic Health Records (EHRs), remote monitoring platforms, and healthcare provider systems, pose significant challenges. The lack of standardized data formats and protocols leads to interoperability issues, hindering effective communication and data sharing. This disparity among software systems results in fragmented information, impeding the seamless flow of data crucial for digital therapeutic monitoring. Furthermore, the integration of data from various sources, such as wearable devices and electronic medical records, encounters hurdle due to differing proprietary formats. This complexity in consolidating and analyzing data hampers the efficiency of digital therapeutic solutions, contributing to implementation delays, increased costs, and obstacles in market growth.
Recent Developments
- In September 2023, GAIA AG launched Amiria which is an innovative depression therapy, offering a fully automated therapeutic software experience. Through advanced technology, it provides personalized and evidence-based interventions, making mental health support more accessible and tailored for individuals seeking effective automated depression treatment and helping to enhance the operating system of the company
- In April 2021, Kaia Health announced a USD 75.00 million Series C round (total raised to date: USD 125.00 million) to expand clinical capabilities and transform the treatment path for Musculoskeletal (MSK) and Chronic Obstructive Pulmonary Disease (COPD) care in the U.S. and Europe
Europe Digital Therapeutics (DTx) Market Scope
The Europe Digital Therapeutics (DTx) market is segmented into four notable segments based on product, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product
- Solutions/Software
- Hardware Products
- Services
On the basis of product, the Europe Digital Therapeutics (DTx) market is segmented into hardware products, solutions/software, and services.
Application
- Preventive
- Treatment
- Others
On the basis of application, the Europe Digital Therapeutics (DTx) market is segmented into treatment, preventive, and others.
End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Other
On the basis of end user, the Europe Digital Therapeutics (DTx) market is segmented into hospitals, specialty clinics, home healthcare, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the Europe Digital Therapeutics (DTx) market is segmented into direct tender, retail sales, and others.
Europe Digital Therapeutics (DTx) Market Regional Analysis/Insights
The Europe Digital Therapeutics (DTx) market is segmented into four notable segments based on product, application, end user, and distribution channel.
The countries covered in this market report are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Denmark, Poland, Sweden, Finland, Norway, and rest of Europe.
Germany is expected to dominate the market due to rising health tech investment and the strong presence of market leaders.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, and regulatory acts are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and the challenges faced due to large or scarce competition from local and domestic brands are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Digital Therapeutics (DTx) Market Share Analysis
The Europe Digital Therapeutics (DTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, company strengths and weaknesses, product launch, product approvals, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in this Europe Digital Therapeutics (DTx) market are Kaia Health, HealthHero, Mindable Health GmbH, GAIA AG, ResMed, and Sidekick Health among others.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE DIGITAL THERAPEUTICS (DTX) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT AND SERVICE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING TECHNOLOGICAL ADVANCEMENTS IN DIGITAL HEALTHCARE DEVICES
5.1.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML)
5.1.3 INCREASING GOVERNMENT SUPPORT AND FUNDING
5.2 RESTRAINTS
5.2.1 DATA SECURITY AND PRIVACY CONCERNS RELATED TO DATA
5.2.2 HIGH LITERACY GAP IN DIGITAL HEALTH WITHIN THE POPULATION
5.3 OPPORTUNITIES
5.3.1 GROWING EXPANSION OF TELEHEALTH APPLICATIONS IN EUROPE
5.3.2 INCREASING FOCUS ON PERSONALIZED DEVICES FOR DIGITAL THERAPEUTICS
5.3.3 INCREASING STRATEGIC COLLABORATIONS AMONG THE MARKET PLAYERS
5.4 CHALLENGES
5.4.1 SOFTWARE INCOMPATIBILITY ISSUES DUE TO VARYING DATA STANDARDS
5.4.2 REGULATORY AND LEGAL CHALLENGES RELATED TO DTX DEVICES
6 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 SOLUTIONS/SOFTWARE
6.2.1 MOBILE APPLICATIONS
6.2.2 WEB BASED PLATFORMS
6.2.3 ELECTRONIC HEALTH RECORDS
6.2.4 OTHERS
6.3 HARDWARE PRODUCTS
6.3.1 WEARABLE DEVICES
6.3.2 REMOTE PATIENT MONITORING DEVICES
6.4 SERVICES
7 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 PREVENTIVE
7.2.1 OBESITY
7.2.2 PREDIABETES
7.2.3 OTHERS
7.3 TREATMENT
7.3.1 CARDIOVASCULAR
7.3.2 MENTAL HEALTH
7.3.3 DIABETES
7.3.4 RESPIRATORY CARE
7.4 OTHERS
8 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL
8.1 OVERVIEW
8.2 DIRECT TENDER
8.3 RETAIL SALES
8.4 OTHERS
9 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME HEALTHCARE
9.5 OTHER
10 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY COUNTRY
10.1 EUROPE
10.1.1 GERMANY
10.1.2 FRANCE
10.1.3 ITALY
10.1.4 SPAIN
10.1.5 U.K.
10.1.6 SWITZERLAND
10.1.7 NETHERLANDS
10.1.8 RUSSIA
10.1.9 TURKEY
10.1.10 POLAND
10.1.11 SWEDEN
10.1.12 BELGIUM
10.1.13 DENMARK
10.1.14 FINLAND
10.1.15 NORWAY
10.1.16 REST OF EUROPE
11 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 HEALTHHERO
13.1.1 COMPANY SNAPSHOT
13.1.2 SERVICE PORTFOLIO
13.1.3 RECENT DEVELOPMENT
13.2 RESMED
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 GAIA AG
13.3.1 COMPANY SNAPSHOT
13.3.2 PRODUCT PORTFOLIO
13.3.3 RECENT DEVELOPMENT
13.4 SIDEKICK HEALTH GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 PRODUCT PORTFOLIO
13.4.3 RECENT DEVELOPMENT
13.5 KAIA HEALTH
13.5.1 COMPANY SNAPSHOT
13.5.2 PRODUCT PORTFOLIO
13.5.3 RECENT DEVELOPMENT
13.6 MINDABLE HEALTH GMBH
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
표 목록
TABLE 1 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 2 EUROPE SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTIC (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 EUROPE HARDWARE PRODUCTS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 5 EUROPE PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 8 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 9 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 10 GERMANY DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 11 GERMANY SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 GERMANY HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 13 GERMANY DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 14 GERMANY PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 GERMANY TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 GERMANY DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 17 GERMANY DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 18 FRANCE DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 19 FRANCE SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 FRANCE HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 FRANCE DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 22 FRANCE PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 FRANCE TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 FRANCE DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 25 FRANCE DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 26 ITALY DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 27 ITALY SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 ITALY HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 ITALY DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 30 ITALY PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 ITALY TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 ITALY DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 33 ITALY DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 34 SPAIN DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 35 SPAIN SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 SPAIN HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 SPAIN DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 38 SPAIN PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 SPAIN TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 40 SPAIN DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 41 SPAIN DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 U.K. DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 43 U.K. SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 U.K. HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 U.K. DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 46 U.K. PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 U.K. TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 U.K. DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 49 U.K. DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 50 SWITZERLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 51 SWITZERLAND SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 SWITZERLAND HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 SWITZERLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 54 SWITZERLAND PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 SWITZERLAND TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 SWITZERLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 57 SWITZERLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 58 NETHERLANDS DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 59 NETHERLANDS SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 60 NETHERLANDS HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 61 NETHERLANDS DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 62 NETHERLANDS PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 NETHERLANDS TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 NETHERLANDS DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 65 NETHERLANDS DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 66 RUSSIA DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 67 RUSSIA SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 RUSSIA HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 RUSSIA DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 70 RUSSIA PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 RUSSIA TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 RUSSIA DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 73 RUSSIA DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 74 TURKEY DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 75 TURKEY SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 TURKEY HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 TURKEY DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 78 TURKEY PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 TURKEY TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 TURKEY DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 81 TURKEY DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 82 POLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 83 POLAND SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 POLAND HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 85 POLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 86 POLAND PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 POLAND TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 POLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 89 POLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 90 SWEDEN DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 91 SWEDEN SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 SWEDEN HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 SWEDEN DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 94 SWEDEN PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 95 SWEDEN TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 SWEDEN DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 97 SWEDEN DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 98 BELGIUM DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 99 BELGIUM SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 BELGIUM HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 BELGIUM DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 BELGIUM PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 BELGIUM TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 BELGIUM DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 105 BELGIUM DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 106 DENMARK DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 107 DENMARK SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 DENMARK HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 DENMARK DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 110 DENMARK PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 DENMARK TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 DENMARK DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 DENMARK DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 FINLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 115 FINLAND SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 FINLAND HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 FINLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 118 FINLAND PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 FINLAND TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 FINLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 121 FINLAND DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 122 NORWAY DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 123 NORWAY SOLUTIONS/SOFTWARE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 NORWAY HARDWARE PRODUCTS IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 125 NORWAY DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 126 NORWAY PREVENTIVE IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 NORWAY TREATMENT IN DIGITAL THERAPEUTICS (DTX) MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 NORWAY DIGITAL THERAPEUTICS (DTX) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 129 NORWAY DIGITAL THERAPEUTICS (DTX) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 130 REST OF EUROPE DIGITAL THERAPEUTICS (DTX) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
그림 목록
FIGURE 1 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: SEGMENTATION
FIGURE 2 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: SEGMENTATION
FIGURE 12 RISING TECHNOLOGICAL ADVANCEMENTS IN THE DISEASE DIAGNOSIS AND TREATMENT APPROACH, INCREASING INVESTMENT IN EARLY STAGE VENTURES, REIMBURSEMENT COVERAGE PROVIDED BY THE REGULATORY AGENCIES ARE SOME OF THE FACTORS EXPECTED TO DRIVE THE EUROPE DIGITAL THERAPEUTICS MARKET IN THE FORECAST PERIOD 2024 TO 2031
FIGURE 13 SOLUTIONS/ SOFTWARES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DIGITAL THERAPEUTICS (DTX) MARKET IN 2024 AND 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE DIGITAL THERAPEUTICS (DTX) MARKET
FIGURE 15 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY PRODUCT, 2023
FIGURE 16 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 17 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 18 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY APPLICATION, 2023
FIGURE 20 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 21 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 22 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 24 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 25 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 26 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 27 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY END USER, 2023
FIGURE 28 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 29 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 30 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: SNAPSHOT (2023)
FIGURE 32 EUROPE DIGITAL THERAPEUTICS (DTX) MARKET: COMPANY SHARE 2023 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
